

Recursos del Bibliotecario 1/14/21

- Development and external validation of a prognostic tool for COVID-19 critical disease (Chow, et.al.):
<https://doi.org/10.1371/journal.pone.0242953>
- COVID-19 Predictive Analytics Tool (CAIDM):
<http://covidrisk.hs.uci.edu/>
- Pfizer/BioNTech vaccine appears effective against mutation in new coronavirus variants -study (Reuters, 8 January 2021):
<https://www.reuters.com/article/health-coronavirus-pfizer-vaccine-int/pfizer-biontech-vaccine-appears-effective-against-mutation-in-new-coronavirus-variants-study-idUSKBN29D1GO>
- Neutralization of N501Y mutant SARS-CoV-2 by BNT162b2 vaccine-elicited sera (Xie, et.al.):
<https://doi.org/10.1101/2021.01.07.425740>
- Impact of B.1.1.7 variant mutations on antibody recognition of linear SARS-CoV-2 epitopes (Haynes, et.al.):
<https://doi.org/10.1101/2021.01.06.20248960>
- Investigation of novel SARS-CoV-2 variant: Variant of Concern 202012/01:
https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/950823/Variant_of_Concern_VOC_202012_01_Technical_Briefing_3_-_England.pdf
- Allergic Reactions Including Anaphylaxis After Receipt of the First Dose of Pfizer-BioNTech COVID-19 Vaccine — United States, December 14–23, 2020 (CDC - MMWR, 6 January 2021):
<http://dx.doi.org/10.15585/mmwr.mm7002e1>
- Early High-Titer Plasma Therapy to Prevent Severe Covid-19 in Older Adults (Libster, et.al.):
<https://doi.org/10.1056/NEJMoa2033700>
- Consideraciones de vacunación para personas con afecciones subyacentes
<https://espanol.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/underlying-conditions.html>
- Interim Clinical Considerations for Use of mRNA COVID-19 Vaccines Currently Authorized in the United States
<https://www.cdc.gov/vaccines/covid-19/info-by-product/clinical-considerations.html>
- SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19
<https://www.nejm.org/doi/full/10.1056/NEJMoa2029849>